Mylan public health patient advocacy
One of the most powerful ways to serve patients in need is by speaking out on their behalf.

Mylan works with government, trade associations, healthcare providers, patient-advocacy groups and others to shape policies that help people across the nation enjoy better health.

MAKING MEDICINE MORE ACCESSIBLE

Mylan has a decades-long track record of expanding people’s access to medicine, particularly by making more-affordable generic versions of brand name drugs – expertise we’re now bringing to biologics, insulins and other complex medicines.

  1. Helped establish the generic industry’s first trade association

    1982
  2. Helped give rise to legislation creating the modern generics industry

    1984
  3. Helped modernize Medicare, including the introduction of a prescription-drug benefit

    2003
  4. Led the way to ensure one quality standard for all medicines sold in the U.S.

    2012
Mylan 19 piechart

In 1984, Generic drugs made up only 19% of prescriptions dispensed in the U.S.

Mylan 90 piechart

In 2017, they made up 90% of prescriptions dispensed

Expanding Access to Biosimilars

Biologics now account for about 40% of all U.S. drug spending and 70% of spending growth from 2010 to 20151. It’s estimated that the introduction of biosimilars in the U.S. could save the nation’s healthcare system up to $150B in savings2. We believe that if restrictive policies and other barriers to entry are addressed, the savings could be even greater.

Policymakers can help unlock the value of biosimilars in the U.S.

  1. Encourage GREATER USE OF BIOSIMILARS,
    especially in Medicare.

    1
  2. Improve access to biosimilars by STOPPING DELAY TACTICS to
    biosimilars such as REMS3 abuse through denied access to samples.

    2
  3. Ensure BALANCED TRADE AND IP4 POLICY
    to expand access to biosimilars.

    3
  4. Enhance biosimilars through APPROPRIATE
    REGULATORY POLICY.

    4
  5. Accelerate GREATER EDUCATION of HCPs5, patients
    and others on safety and reliability of biosimilars.

    5

Addressing an important need in schools

Epinephrine is the only first-line treatment for anaphylaxis, a potentially life-threatening allergic reaction.
  • Several years ago, we recognized that epinephrine auto-injectors needed to be as accessible as defibrillators are in public spaces.
  • Since then, Mylan advocated for legislation to permit “undesignated” epinephrine auto-injectors in schools – meaning a prescription could be in a school’s name rather than in a child’s name and any individual experiencing an anaphylactic reaction would have access to the epinephrine autoinjectors.
Today, 48 states have adopted such laws, and Mylan has donated more than 1 million epinephrine auto-injectors to more than 73,000 schools around the country.

Stemming the Tide of HIV/AIDS

Helping those in need is a gift that benefits everyone. Mylan is the world’s largest producer of HIV/AIDS drugs.

>40%

of all people worldwide being treated for HIV/ AIDS depend on a Mylan antiretroviral product.

>50%

of Mylan’s active pharmaceutical ingredient manufacturing capacity is devoted to antiretrovirals.

Learn More